… Erlotinib maintenance therapy significantly prolonged PFS in … The erlotinib-related OS
benefit in the SD group remained … erlotinib treatment did not negatively impact quality of life. …

… In conclusion, we demonstrate that maintenance therapy with EGFR TKIs (gefitinib and
erlotinib) produces a significant PFS and OS benefit for patients with advanced NSCLC …

… Maintenance therapy with erlotinib for patients with NSCLC is well tolerated and significantly
prolongs PFS compared with placebo. First-line maintenance with erlotinib could be …

… with squamous cell cancer benefit from erlotinib maintenance chemotherapy, and the lack …
benefit associated with erlotinib maintenance therapy, compared with placebo therapy, in the …

… in the median PFS with erlotinib maintenance therapy. This improved PFS persisted over
time, and the 6-month PFS was 40.3% versus 28.4% in the erlotinib and the placebo groups, …

… demonstrated that maintenance therapy with erlotinib after the first… tolerability of erlotinib
maintenance in daily clinical practice. … erlotinib maintenance to erlotinib second-line therapy, the …

… Maintenance therapy with erlotinib was well tolerated and … early’ maintenance erlotinib
therapy (postchemotherapy, but prior to progression) versus ‘late’ second-line erlotinib therapy (ie …

… of oral erlotinib as monotherapy for maintenance treatment in … use of erlotinib as monotherapy
for maintenance therapy in … basis for the approval of erlotinib maintenance therapy in this …

… Maintenance therapy can delay progression and prolong survival in metastatic non-small-…
study investigating the impact of erlotinib maintenance therapy on HRQoL in patients with …

… Erlotinib is an EGFR TKI that prolongs survival in p with recurrent and metastatic NSCLC. In
this study, we aim to evaluate the role of erlotinib as maintenance therapy … received erlotinib …